A paradigm shift may be imminent concerning the development and commercialization of pharma products and new medicines, according to Ulrich Neumann of Eyeforpharma. Neumann discusses the idea that the clinical trial process to bring new drugs to market should become...
ClinLab Staffing
Top Five IPOs of 2014
The first six months of 2014 have seen as many pharmaceutical initial public offerings as the whole of 2013. A total of 52 IPOs have been completed in 2014, whereas 2013 saw a total of 54 IPOs. The industry is experiencing heightened investment activity now that the...
New FDA/EU Agreement Creates a More Efficient and Safer Drug Supply
The media hub, Eye for Pharma, has reported on the new relaxed rules concerning the export of drugs to the European Union (EU). Additional documentation is no longer required by exporting pharma companies because the US has been granted “listed” country status by the...
FDA Breakthrough Programs Take Years off the Approval Process
The Food and Drug Administration (FDA) is being congratulated on a breakthrough in the conventional belabored FDA approval process. Ben Steele, contributor to Eye for Pharma reported that the pharmas Johnson & Johnson and Vertex Pharmaceuticals spoke out in...
Controlling Cholesterol through R&D
Drug developers are spending billions on R&D and extensive studies on treatments for high cholesterol based on genomic sequencing. According to Damian Garde of Fiercebiotech, Amgen is the current leader and may be the first to launch a new drug; the company is...
What were the Top Experimental Cancer Drugs in 2013?
Many pharma companies are developing new cancer treatment drugs to meet the demand by doctors and patients. According to FierceBiotech, regulators are helping pharmas bring these new treatments to market by reducing the required clinical trial phases for certain...